BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/28/2020 1:45:46 AM | Browse: 78 | Download: 88
Publication Name World Journal of Clinical Cases
Manuscript ID 57136
Country/Territory Italy
Received
2020-05-26 22:26
Peer-Review Started
2020-05-26 22:28
To Make the First Decision
Return for Revision
2020-06-15 17:40
Revised
2020-08-20 17:37
Second Decision
2020-09-07 10:15
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2020-09-08 00:50
Articles in Press
2020-09-08 00:50
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2020-09-14 11:13
Publish the Manuscript Online
2020-09-28 01:45
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Infectious Diseases
Manuscript Type Opinion Review
Article Title Role of monoclonal antibody drugs in the treatment of COVID-19
Manuscript Source Unsolicited Manuscript
All Author List Claudio Ucciferri, Jacopo Vecchiet and Katia Falasca
ORCID
Author(s) ORCID Number
Claudio Ucciferri http://orcid.org/0000-0002-5866-3849
Jacopo Vecchiet http://orcid.org/0000-0001-9250-4844
Katia Falasca http://orcid.org/0000-0002-8795-5410
Funding Agency and Grant Number
Corresponding Author Katia Falasca, MD, PhD, Associate Professor, Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University “G. d’Annunzio” Chieti-Pescara, Via dei Vestini, Chieti 66100, Italy. k.falasca@unich.it
Key Words Tocilizumab; Anakinra; Canakinumab; Ruxolitinib; Clazakizumab; Siltuximab
Core Tip Elevated inflammatory cytokines have been reported in patients with coronavirus disease 2019 (COVID-19). Evidence suggests that elevated cytokine levels and high levels in inflammatory markers are responsible for multi-organ damage in patients with COVID 19. Numerous randomized clinical trials are currently underway to explore the effectiveness of interleukin-1 blockers, interleukin-6 inhibitors. Or other strategies. For this reason it is necessary to make the point about using biopharmaceutical drugs in COVID 19.
Publish Date 2020-09-28 01:45
Citation Ucciferri C, Vecchiet J, Falasca K. Role of monoclonal antibody drugs in the treatment of COVID-19. World J Clin Cases 2020; 8(19): 4280-4285
Url https://www.wjgnet.com/2307-8960/full/v8/i19/4280.htm
DOI https://dx.doi.org/10.12998/wjcc.v8.i19.4280
Full Article (PDF) WJCC-8-4280.pdf
Full Article (Word) WJCC-8-4280.docx
Manuscript File 57136-Review.docx
Answering Reviewers 57136-Answering reviewers.pdf
Audio Core Tip 57136-Audio core tip.opus
Conflict-of-Interest Disclosure Form 57136-Conflict-of-interest statement.pdf
Copyright License Agreement 57136-Copyright license agreement.pdf
Peer-review Report 57136-Peer-review(s).pdf
Scientific Misconduct Check 57136-Scientific misconduct check.pdf
Scientific Editor Work List 57136-Scientific editor work list.pdf